🌿 Acellular Wharton’s Jelly Therapy

A Growth Factor–Rich Solution for Regenerative Healing

What Is Acellular Wharton’s Jelly?

Acellular Wharton’s Jelly is a form of regenerative therapy made from the gel-like tissue inside donated umbilical cords, but without any live cells. During processing, the cellular components are removed, leaving behind a powerful blend of natural healing substances, including:

  • Growth factors
  • Cytokines
  • Collagen
  • Hyaluronic acid
  • Extracellular matrix (ECM) proteins¹

These ingredients work together to reduce inflammation, promote repair of damaged tissue, and signal your body’s own cells to begin healing.

Why Use Acellular Instead of Cellular?

Acellular Wharton’s Jelly may not contain live stem cells, but it still delivers a biological message to your body that starts the healing process. It offers many of the same benefits as cellular versions—especially for reducing pain, inflammation, and improving joint function.

It’s often chosen for patients who:

  • May not be candidates for live cell therapies
  • Prefer a therapy with zero cellular material
  • Want a more affordable regenerative option
  • Are focused on anti-inflammatory and pain-relieving effects²

How It Works

  1. Injection: The acellular Wharton’s Jelly is injected into the joint, tendon, or soft tissue using imaging guidance for accuracy.
  2. Healing Response: The proteins and growth factors trigger local healing, reduce inflammation, and recruit your body’s natural repair systems.
  3. Relief Over Time: Most patients begin to notice improvement in function and pain relief over the following weeks.

Conditions Treated

At Johnson Medical Center, we use Acellular Wharton’s Jelly to help patients with:

  • Osteoarthritis (knees, hips, shoulders, spine)
  • Joint inflammation and stiffness
  • Tendon and ligament injuries
  • Post-surgical recovery
  • Chronic pain that has not responded to other therapies

Safety and Quality

Acellular Wharton’s Jelly is sourced from ethically donated umbilical cord tissue following full-term births. The product is processed in FDA-registered, cGMP-compliant labs that ensure sterility, quality, and safety.

Because the product is acellular, the risk of immune reaction or rejection is virtually zero³.

A Safe, Non-Cellular Path to Healing

For patients seeking an inflammation-reducing, regenerative treatment that does not involve live cells, Acellular Wharton’s Jelly is a valuable option. It helps your body move toward healing naturally and effectively, especially when combined with physical medicine.

🔗 Sources
  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334106/
  2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833064/
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396575/

Regulatory Information

Johnson Medical Center is fully committed to complying with all Florida state and FDA regulations. Our MSC therapies are offered under approved protocols to ensure patient safety and regulatory adherence.

Before treatment, our patients receive detailed information about the investigational nature of MSC therapies, including potential risks and benefits, as required by Florida law. We are committed to ensuring you make an informed decision about your care.

Our umbilical cord-derived MSC therapies are processed in facilities that comply with FDA’s current Good Manufacturing Practices (cGMP) and Florida state regulations, ensuring the highest standards of safety and quality.

The mesenchymal signaling cell (MSC) therapies offered at Johnson Medical Center are investigational and not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of arthritic joint conditions or soft tissue injuries. These therapies are provided under an FDA-approved clinical trial or expanded access program. Patients should be aware that experimental treatments carry risks, including infection or lack of efficacy, and should discuss these with their healthcare provider. To report any adverse events, please contact the FDA’s MedWatch program at www.fda.gov/medwatch or 1-800-FDA-0178.

In compliance with Florida law, Johnson Medical Center informs patients that our mesenchymal signaling cell (MSC) therapies are not approved by the FDA for the treatment of arthritic joint conditions or soft tissue injuries. Our clinic is registered with the Florida Department of Health, lab adheres to FDA manufacturing standards, and undergoes annual state inspections. During the informed consent process, we provide detailed information about the investigational nature of these therapies, including potential risks and benefits.